Abstract 

Omega-3 fatty acids are often described as anti-inflammatory. Current evidence shows a more precise role: EPA and DHA act as substrates for specialised pro-resolving mediators (SPMs) that complete the inflammatory response rather than simply suppressing it. This review outlines how resolution biology informs regenerative aesthetic practice – supporting orderly healing, collagen remodelling, and barrier recovery – alongside a pragmatic, test-based approach to optimisation. Understanding omega-3 status through the lens of resolution may help clinicians improve post-procedure trajectories and patient experience. 

Keywords: omega-3; EPA; DHA; resolution biology; specialised pro-resolving mediators; aesthetic medicine; inflammageing 

Introduction 

It turns out our mothers were onto something when they insisted on that daily spoonful of cod liver oil – though they probably didn’t realise quite how sophisticated their intuition was. Framing omega-3 fatty acids as ‘anti-inflammatory’ is a useful start but actually is incomplete.  

Long-chain marine omega-3s – eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) – are precursors for specialised pro-resolving mediators (SPMs), including resolvins, protectins, and maresins.¹’² These lipid mediators actively coordinate the completion of inflammation and the return to tissue homeostasis, which is the terrain we rely on for predictable aesthetic outcomes.³  

My work translating this complex science for patients and clinicians, most recently in Busting The Code To Ageing: How to Win the Inflammation Game, focuses on making resolution biology operational in day-to-day practice. 

The omega imbalance: a global clinical reality 

Modern diets have shifted the omega-6:omega-3 ratio from historical estimates near 3:1 to >15-20:1 for many people.⁴ Large dried blood spot datasets (>500,000 samples) report median continental ratios around 6.2:1 to 8.8:1, with substantial tails to the right.⁵ That mirrors clinic experience: even health-conscious patients often present with ratios near 17:1 despite ‘good’ diets and occasional fish oil. Internal surveillance further suggests that the majority tested do not reach a 3:1 target, and many do not supplement at all.⁶ 

Why this matters in aesthetics: When omega-6 dominates membrane composition, cells become less flexible and signalling skews toward arachidonic acid eicosanoids. When membranes become rigid, receptors and channels can’t move or signal properly – so you can’t get the good stuff in (nutrients, hormones) or the bad stuff out (waste, toxins), slowing repair, weakening the barrier, and heightening inflammatory stress.7 

Clinically, that correlates with slower barrier repair, higher oxidative burden, more MMP activity, and less predictable remodelling – all of which can complicate post-procedure recovery.8 From a resolution perspective, high AA:EPA also means fewer substrates available for resolvins at the moment they are needed.⁵ 

Resolution biology: beyond anti-inflammation 

SPMs do four things that practitioners should care about:9 

1. They limit further neutrophil influx 

1. They promote efferocytosis – the process by which immune cells (particularly macrophages) recognise, engulf, and clear apoptotic cells from tissues. When this cellular cleanup system becomes overwhelmed or inefficient (which happens with ageing), dead cells aren’t cleared efficiently, leading to chronic inflammation. From my clinical perspective, impaired efferocytosis is one of the underlying mechanisms driving chronic low-grade inflammation that accelerates skin ageing. 

1. They cue macrophages toward a pro-resolving state 

1. They help restore tissue tone without broad immunosuppression 

Put simply: they do not just turn inflammation ‘down’; they help finish it in an orderly way. EPA provides E-series resolvins, while DHA gives rise to D-series resolvins, protectins, and maresins – each with tissue-specific effects that matter in skin and connective tissue.9,10 

EPA and DHA: distinct but complementary 

EPA (eicosapentaenoic acid): Think of EPA as your inflammation moderator. It competes with arachidonic acid for the same enzymes (cyclooxygenase and lipoxygenase, the pathways that create inflammatory signals), effectively crowding out the troublemakers whilst supplying the raw materials for E-series resolvins. In practice, patients with optimal EPA levels tend to have more predictable inflammatory responses: less dramatic redness, quicker settling of reactivity, and better microcirculation. This is particularly valuable when we’re working with sensitive skin or managing post-procedure recovery.11 

DHA (docosahexaenoic acid): DHA is your brain and nerve tissue specialist, making up about 30% of brain grey matter. It keeps cellular membranes fluid and flexible, which means receptors can function properly and cells can communicate effectively. Beyond the neurological benefits, DHA provides D-series resolvins and protectins that support the brain-immune connection, which is crucial for maintaining good sleep patterns and stress resilience, both of which directly impact how well your skin heals and recovers. When patients aren’t sleeping well or managing stress effectively, their healing suffers, so DHA’s role in neuro-immune stability becomes clinically relevant.12 

Clinical testing and implementation 

Assumption is unreliable; numbers guide care. The Omega-3 Index (%EPA+DHA in erythrocyte membranes) gives a practical readout of tissue status; many programmes aim for ≥8%.12 

The omega-6:omega-3 (or AA:EPA) ratio adds context; trending toward ≤3:1 is a pragmatic target. A 120-day retest aligns with erythrocyte turnover and provides a meaningful proof point for patients and teams.5 

Therapeutic implementation 

Dietary pattern: 

• Mediterranean-leaning: oily fish 2-3×/week; polyphenol-rich plants; extra virgin olive oil; reduce concentrated seed oil omega-6 and ultra-processed foods. 

Supplementation (when diet alone is insufficient): 

• Typical clinical range: Clinical dosing recommendations are based on EFSA-approved therapeutic ranges and multiple clinical trials demonstrating efficacy at 2-3 g/day combined EPA+DHA for 12-24 weeks. 

• Forms and timing: triglyceride or re-esterified TG forms with meals; split doses for GI comfort; adjust by body weight, baseline, and response.9,11 

Clinical applications in aesthetic medicine 

Pre-/post-procedure optimisation (8-12 weeks): Building omega-3 status ahead of procedures creates better working conditions. The evidence shows that EPA and DHA act as precursors to signalling molecules that increase blood flow to the skin and boost collagen and elastin production – both essential for tissue resilience and repair.13 Animal studies demonstrate that the 12/15-lipoxygenase pathway (which processes omega-3s into resolvins) actively promotes epithelial wound healing,14 while human trials show measurable improvements in skin elasticity over 60-200 days of optimisation.15 

Clinically, patients with better omega-3 status tend to present with more predictable inflammatory responses, less dramatic erythema, and steadier collagen remodelling trajectories – though prospective controlled data specific to aesthetic procedures remains limited. 

Important peri-procedure note: Omega-3s exhibit dose-dependent anti-platelet effects. Studies show that while 1.8g EPA daily doesn’t prolong bleeding time, doses above 4g daily can increase bleeding time and reduce platelet counts – though, notably, clinical bleeding events have not been reported even in patients undergoing angioplasty while taking fish oil supplements.16 That said, most perioperative protocols err on the side of caution. Discontinuing supplementation 72 hours before invasive procedures and resuming 24-48 hours post-haemostasis is common clinical practice, though these specific timeframes reflect pharmacokinetic principles rather than procedural trial data. 

Reactive skin and midlife transitions: omega-3 optimisation alongside barrier repair may reduce volatility. As oestrogen declines in midlife, skin becomes more reactive and recovery slows. Optimising omega-3 intake – especially DHA – can help buffer inflammation and support skin health. Pairing this with targeted barrier repair reduces skin volatility, while maintaining good sleep routines further anchors recovery and resilience. Research supports the role of omega-3 fatty acids in managing inflammatory skin conditions and promoting barrier function, particularly during hormonal transitions.17 

Integration with comprehensive protocols 

Omega-3 optimisation amplifies, not replaces, fundamentals: consistent sleep (protect 22:00-02:00), morning light, resistance training, and minimally processed nutrition. Late-night glucose spikes and high omega-6 loads can outpace resolution capacity even with supplementation.17 

Conclusion 

Reframing omega-3s as resolution substrates is clinically useful. EPA and DHA provide the raw materials for SPMs that complete inflammation, supporting the conditions needed for orderly remodelling and barrier recovery.  

A simple workflow – assess with dried blood spot testing, address with diet and targeted dosing, and retest at 120 days – fits neatly alongside existing aesthetic pathways and helps set realistic expectations for patients: we are not trying to eliminate inflammation; we are helping it finish properly.